BRIEF-Ascidian Therapeutics Announces Global Research Collaboration Licensing Agreement With Eli Lilly

Eli Lilly

Eli Lilly

LLY

0.00

June 3 (Reuters) - Ascidian Therapeutics:

  • ASCIDIAN THERAPEUTICS: ANNOUNCES GLOBAL RESEARCH COLLABORATION LICENSING AGREEMENT WITH ELI LILLY

  • ASCIDIAN THERAPEUTICS: LILLY TO RECEIVE EXCLUSIVE TARGET-SPECIFIC RIGHTS TO CO'S RNA EXON EDITING TECHNOLOGY FOR UNDISCLOSED KIDNEY DISEASE TARGETS

  • ASCIDIAN THERAPEUTICS: ELIGIBLE TO RECEIVE UP TO $1.9 BLN

  • ASCIDIAN THERAPEUTICS: UNDER DEAL, LILLY RESPONSIBLE FOR ADDITIONAL CLINICAL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION

  • ASCIDIAN THERAPEUTICS: RETAINS RIGHT TO PURSUE OTHER TARGETS IN KIDNEY DISEASE PROGRAMS INDEPENDENTLY OR WITH ADDITIONAL PARTNERS


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.